In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()

The fibroblast growth factor receptor (FGFR) pathway has been implicated both as an escape mechanism from anti-angiogenic therapy and as a driver oncogene in different tumor types. Lucitanib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1 to 3 (VEGFR1 to 3), pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Guffanti, Federica, Chilà, Rosaria, Bello, Ezia, Zucchetti, Massimo, Zangarini, Monique, Ceriani, Laura, Ferrari, Mariella, Lupi, Monica, Jacquet-Bescond, Anne, Burbridge, Mike F., Pierrat, Marie-Jeanne, Damia, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167242/
https://www.ncbi.nlm.nih.gov/pubmed/27988457
http://dx.doi.org/10.1016/j.neo.2016.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167242/
https://www.ncbi.nlm.nih.gov/pubmed/27988457
http://dx.doi.org/10.1016/j.neo.2016.11.008

Ejemplares similares